高林 哲司 たかばやし てつじ 先生

来歴等

略歴

1997年 福井医科大学（現・福井大学医学部） 卒業
1997年 福井医科大学（現・福井大学医学部）附属病院 耳鼻咽喉科 医員（研修医）
2002年 福井医科大学（現・福井大学医学部）附属病院 耳鼻咽喉科 医員
2006年 舞鶴共済病院 耳鼻咽喉科 部長
2009年 福井大学医学部 耳鼻咽喉科頭頸部外科 助教
2010年 米国ノースウェスタン大学免疫アレルギー教室 研究員
2013年 福井大学医学部 耳鼻咽喉科頭頸部外科 助教
2015年 福井大学医学部 耳鼻咽喉科頭頸部外科 講師
2023年 福井大学医学部 耳鼻咽喉科頭頸部外科 准教授

もっと見る

論文

• 1.Retinoic acid promotes fibrinolysis and may regulate polyp formation. J Allergy Clin Immunol. 2022 Nov;150(5):1114-1124.e3.

  Sakashita M, Takabayashi T, Imoto Y, Homma T, Yoshida K, Ogi K, Kimura Y, Kato A, Stevens WW, Smith SS, Welch KC, Norton JE, Suh LA, Carter RG, Hulse KE, Seshadri S, Min JY, Pothoven KL, Conley DB, Tan BK, Harris KE, Kern RC, Haruna S, Matsuwaki Y, Ochiai R, Fujieda S, Schleimer RP.

• 2.Regulation of the Expression of SARS-CoV-2 Receptor Angiotensin-Converting Enzyme 2 in Nasal Mucosa. Am J Rhinol Allergy. 2022 Jan;36(1):115-122.

  Takabayashi T, Yoshida K, Imoto Y, Schleimer RP, Fujieda S.

• 3.ORMDL3 overexpression facilitates FcεRI-mediated transcription of proinflammatory cytokines and thapsigargin-mediated PERK phosphorylation in RBL-2H3 cells. Immun Inflamm Dis. 2021 Dec;9(4):1394-1405.

  Ogi K, Takabayashi T, Tomita K, Sakashita M, Morikawa T, Ninomiya T, Okamoto M, Narita N, Fujieda S.

• 4.Involvement of Activation of Mast Cells via IgE Signaling and Epithelial Cell-Derived Cytokines in the Pathogenesis of Pollen Food Allergy Syndrome in a Murine Model. J Immunol. 2021 Jun 15;206(12):2791-2802.

  Kato Y, Morikawa T, Kato E, Yoshida K, Imoto Y, Sakashita M, Osawa Y, Takabayashi T, Kubo M, Miura K, Noguchi E, Fujieda S.

• 5.Increased Thrombin-Activatable Fibrinolysis Inhibitor in Response to Sublingual Immunotherapy for Allergic Rhinitis. Laryngoscope. 2021 Apr 12. doi: 10.1002/lary.29563. Online ahead of print.(IF 2.465)

  Yoshida K, Takabayashi T, Imoto Y, Sakashita M, Kato Y, Narita N, Fujieda S.

• 6.A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis. Am J Rhinol Allergy. 2021 Apr 11:19458924211009429. doi: 10.1177/19458924211009429. Online ahead of print.(IF 1.943)

  Takabayashi T, Asaka D, Okamoto Y, Himi T, Haruna S, Yoshida N, Kondo K, Yoshikawa M, Sakuma Y, Shibata K, Suzuki M, Kobayashi M, Kawata R, Tsuzuki K, Okano M, Higaki T, Takeno S, Kodama S, Yonekura S, Saito H, Nozaki A, Otori N, Fujieda S.

• 7.Baicalin suppresses type 2 immunity through breaking off the interplay between mast cell and airway epithelial cell. J Ethnopharmacol. 2021 Mar 1;267:113492.

  Yoshida K, Takabayashi T, Kaneko A, Takiyama M, Sakashita M, Imoto Y, Kato Y,Narita N, Fujieda S.

• 8.Enhanced 15-Lipoxygenase 1 Production is Related to Periostin Expression and Eosinophil Recruitment in Eosinophilic Chronic Rhinosinusitis. Biomolecules. 2020 Nov 18;10(11):1568.

  Imoto Y, Takabayashi T, Sakashita M, Kato Y, Yoshida K, Kidoguchi M, Koyama K, Adachi N, Kimura Y, Ogi K, Ito Y, Kanno M, Okamoto M, Narita N, Fujieda S.

• 9.Formation of Nasal Polyps: The Roles of Innate Type 2 Inflammation and Deposition of Fibrin. J Allergy Clin Immunol. 2020 Mar;145(3):740-750. * Corresponding author

  Takabayashi T, Schleimer RP.

• 10.Association between the NOS2 pentanucleotide repeat polymorphism and risk of postoperative recurrence of chronic rhinosinusitis with nasal polyps in a Japanese population. Allergol Int. 2020 Oct;69(4):619-621.

  Kidoguchi M, Yoshida K, Noguchi E, Nakamura T, Morii W, Haruna T, Okano M, Yamashita Y, Haruna S, Hasegawa M, Yoshida N, Ninomiya T, Imoto Y, Sakashita M, Takabayashi T, Fujieda S.

• 11.Eosinophilic chronic rhinosinusitis. Allergol Int. 2019 Oct;68(4):403-412.

  Fujieda S, Imoto Y, Kato Y, Ninomiya T, Tokunaga T, Tsutsumiuchi T, Yoshida K, Kidoguchi M, Takabayashi T.

• 12.Increased thrombin-activatable fibrinolysis inhibitor levels in patients with chronic rhinosinusitis with nasal polyps. Allergy Clin Immunol. 2019 Dec;144(6):1566-1574.e6.

  Imoto Y, Kato A, Takabayashi T, Stevens W, Norton JE, Suh LA, Carter RG, Weibman AR, Hulse KE, Harris KE, Peters AT, Grammer LC, Tan BK, Welch K, Shintani-Smith S, Conley DB, Kern RC, Fujieda S, Schleimer RP.

• 13.Increased expression of L-plastin in nasal polyp of patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease. Allergy. 2019 Jul;74(7):1307-1316.

  Takabayashi T, Tanaka Y, Susuki D, et al.

• 14.Reduced Nasal Nitric Oxide Levels in Patients with Eosinophilic Chronic Rhinosinusitis. Allergol Int. 2019 Apr;68(2):225-232.

  Yoshida K, Takabayashi T, Imoto Y, et al.

• 15.Combination Therapy with Montelukast and Loratadine Alleviates Pharyngolaryngeal Symptoms Related to Seasonal Allergic Rhinitis. J Allergy Clin Immunol Pract. 2019 Mar;7(3):1068-1070.e3.

  Imoto Y, Takabayashi T, Sakashita M, Tokunaga T, Morikawa T, Ninomiya T, Okamoto M, Narita N, Fujieda S.

• 16.Expression and Functional Analysis of CST1 in Intractable Nasal Polyps. Am J Respir Cell Mol Biol. 2018 Oct;59(4):448-457.

  Kato Y, Takabayashi T, Sakashita M, Imoto Y, Tokunaga T, Ninomiya T, Morikawa T, Yoshida K, Noguchi E, Fujieda S.

• 17.DNA Methylation of Proximal PLAT Promoter in Chronic Rhinosinusitis with Nasal Polyps. Am J Rhinol Allergy. 2018 Sep;32(5):374-379.

  Kidoguchi M, Noguchi E, Nakamura T, Ninomiya T, Morii W, Yoshida K, Morikawa T, Kato Y, Imoto Y, Sakashita M, Takabayashi T, Fujieda S.

• 18.Periostin as a novel biomarker for postoperative recurrence of chronic rhinosinitis with nasal polyps. Sci Rep. 2018 Jul 30;8(1):11450.

  Ninomiya T, Noguchi E, Haruna T, Hasegawa M, Yoshida T, Yamashita Y, Okano M, Yoshida N, Haruna S, Sakuma Y, Ohta S, Ono J, Izuhara K, Okada M, Kidoguchi M, Tokunaga T, Okamoto M, Kanno M, Sakashita M, Takabayashi T, Narita N, Fujieda S.

• 19.Short-chain fatty acids induce tissue plasminogen activator in airway epithelial cells via GPR41&43. Clin Exp Allergy. 2018 May;48(5):544-554.

  Imoto Y, Kato A, Takabayashi T, Sakashita M, Norton JE, Suh LA, Carter RG, Weibman AR, Hulse KE, Stevens W, Harris KE, Peters AT, Grammer LC, Tan BK, Welch K, Conley DB, Kern RC, Fujieda S, Schleimer RP.

• 20.The significant expression of TRPV3 in nasal polyps of eosinophilic chronic rhinosinusitis. Allergol Int. 2017 Oct;66(4):610-616.

  Tokunaga T, Ninomiya T, Kato Y, Imoto Y, Sakashita M, Takabayashi T, Noguchi E, Fujieda S.

• 21.Nattokinase, profibrinolytic enzyme, effectively shrinks the nasal polyp tissue and decreases viscosity of mucus. Allergol Int. 2017 Oct;66(4):594-602.

  Takabayashi T, Imoto Y, Sakashita M, Kato Y, Tokunaga T, Yoshida K, Narita N, Ishizuka T, Fujieda S.

• 22.Trimellitic anhydride induces low-grade mast cell degranulation without specific IgE. Toxicol Rep. 2016 Sep 7;3:701-707.

  Ogi K, Takabayashi T, Yamada T, Sakashita M, Kanno M, Narita N, Fujieda S.

• 23.Peripheral basophil reactivity, CD203c expression by Cryj1 stimulation, is useful for diagnosing seasonal allergic rhinitis by Japanese cedar pollen. Immun Inflamm Dis. 2015 Sep;3(3):300-8.

  Imoto Y, Takabayashi T, Sakashita M, Tokunaga T, Ninomiya T, Ito Y, Narita N, Yamada T, Fujieda S.

• 24.Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study. Allergy. 2015 Aug;70(8):995-1003.

  Tokunaga T, Sakashita M, Haruna T, Asaka D, Takeno S, Ikeda H, Nakayama T, Seki N, Ito S, Murata J, Sakuma Y, Yoshida N, Terada T, Morikura I, Sakaida H, Kondo K, Teraguchi K, Okano M, Otori N,　Yoshikawa M, Hirakawa K, Haruna S, Himi T, Ikeda K, Ishitoya J, Iino Y, Kawata R, Kawauchi H, Kobayashi M, Yamasoba T, Miwa T, Urashima M, Tamari M, Noguchi E, Ninomiya T, Imoto Y, Morikawa T, Tomita K, Takabayashi T, Fujieda S.

• 25.Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease. Am J Respir Crit Care Med. 2015 Sep 15;192(6):682-94.

  Stevens WW, Ocampo CJ, Berdnikovs S, Sakashita M, Mahdavinia M, Suh L, Takabayashi T, Norton JE, Hulse KE, Conley DB, Chandra RK, Tan BK, Peters AT, Grammer LC 3rd, Kato A, Harris KE, Carter RG, Fujieda S, Kern RC, Schleimer RP.

• 26.Increased expression of factor XIII-A in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2013;132(3):584-592.

  Takabayashi T, Kato A, Peters AT, Hulse KE, Suh LA, Carter R, Norton J, Grammer LC, Tan BK, Chandra RK, Conley DB, Kern RC, Fujieda S, Schleimer RP.

• 27.Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression. Am J Respir Crit Care Med. 2013;187(1):49-57.

  Takabayashi T, Kato A, Peters AT, Hulse KE, Suh LA, Carter R, Norton J, Grammer LC, Tan BK, Chandra RK, Conley DB, Kern RC, Fujieda S, Schleimer RP.

• 28.Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2012;130(2):410-20.

  Takabayashi T, Kato A, Peters AT, Hulse KE, Suh LA, Carter R, Norton J, Grammer LC, Tan BK, Chandra RK, Conley DB, Kern RC, Fujieda S, Schleimer RP.

• 29.LL5beta directs the translocation of filamin A and SHIP2 to sites of phosphatidylinositol 3,4,5-triphosphate (PtdIns(3,4,5)P3) accumulation, and PtdIns(3,4,5)P3 localization is mutually modified by co-recruited SHIP2. J Biol Chem. 2010 May 21;285(21):16155-65.

  Takabayashi T, Xie MJ, Takeuchi S, Kawasaki M, Yagi H, Okamoto M, Tariqur RM, Malik F, Kuroda K, Kubota C, Fujieda S, Nagano T, Sato M.

• 30.Lipopolysaccharides increase the amount of CXCR4, and modulate the morphology and invasive activity of oral cancer cells in a CXCL12-dependent manner. Oral Oncol. 2009 Nov;45(11):968-73.

  Takabayashi T, Takahashi N, Okamoto M, Yagi H, Sato M, Fujieda S.

もっと見る

著書

• 1.医学のあゆみ.「花粉症における上皮性サイトカインの関与」.医歯薬出版.2013.247 (12/13) 1208-1212.

• 2.Monthly Book　ENTONI.「上気道好酸球性炎症と気道アレルギー」.全日本病院出版会.No.170,2014年8月号.

• 3.別冊BIO Clinica「慢性炎症と疾患　好酸球性副鼻腔炎における鼻茸の発症とその難治化の機序」.北隆館.第5巻第2号.

• 4.Monthly Book　ENTONI.「抗アレルギー薬」.全日本病院出版会.No. 240, 1月号.

• 5.Monthly Book　ENTONI.「好酸球性副鼻腔炎に対する生物学的製剤の使い方」.全日本病院出版会.No. 270, 1月号.

• 6.アレルギーの臨床. 好酸球性副鼻腔炎の診断と最近の治療.北隆館.2021年12月号.

• 7.耳鼻咽喉科.「正しい漢方の選び方　好酸球性副鼻腔炎」.2023年4月1/3.p324-333

• 8.耳鼻臨床.「好酸球性副鼻腔炎に対する薬物治療の現状」 .114：10；000〜000,2021.

• 9.「好酸球性副鼻腔炎におけるtype2炎症と凝固・線溶系異常による鼻茸形成」.日本耳鼻咽喉科免疫アレルギー感染症学会誌. 1(3): 000?000, 2021.

• 10.Total Allergistのための分子標的薬治療の手引き .日本アレルギー学会.2022年度版.

• 11.「好酸球性副鼻腔炎における分子標的治療薬の使い方」.全日本病院出版界.2022/5.

• 12.プラクティス耳鼻咽喉科の臨床（耳鼻咽喉科の薬物治療）「漢方薬Topic」.中山書店.

• 13.耳鼻咽喉科・頭頸部外科における最先端研究2022.「好酸球性副鼻腔炎」耳鼻咽喉科.2（5）： 1 -9, 2022.

• 14.日本耳鼻咽喉科頭頸部外科学会会報.専攻医トレーニング講座.「慢性副鼻腔炎の病態分類」. 125 巻, 11 号.

• 15.耳鼻咽喉科薬物治療ベッドサイドガイド.「漢方薬」.中山書店.

• 16.「アレルギー性副鼻腔炎の鼻手術.好酸球性副鼻腔炎（ECRS）治療概論」.医薬情報研究所.

• 17.アレルギー性鼻炎、慢性副鼻腔炎の薬物療法.「好酸球性副鼻腔炎に対する生物学的製剤の現状と将来」.全日本病院出版社.

• 18.免疫・アレルギー疾患における分子標的薬の使い方「好酸球性副鼻腔炎における分子標的治療薬の使い方」. 北隆社.

• 19.今日の治療指針2024.「慢性副鼻腔炎」.

もっと見る